- Email: [email protected]
Attenuation of Cardiac Allograft Vasculopathy in Dual Organ Transplantation
S154
The Journal of Heart and Lung Transplantation, Vol 36, No 4S, April 2017
Conclusion: Those with end-stage heart failure and renal failure represent a critically ill cohort of OHT candidates. In those requiring dialysis after listing for OHT, a SHK strategy confers superior survival compared to HTA or KAH. Future revisions to organ allocation should take into account both the appropriateness of SHK, as well as superiority of SHK over sequential transplant strategies.
3( 93)
3( 92) Attenuation of Cardiac Allograft Vasculopathy in Dual Organ Transplantation K.J. Clerkin ,1 S.W. Restaino,1 F. Latif,1 M.A. Farr,1 E. Zorn,2 D.M. Mancini,3 K. Takeda,4 H. Takayama,4 Y. Naka,4 P.C. Colombo,1 V.K. Topkara.1 1Cardiology, Columbia University Medical Center, New York, NY; 2Immunology, Columbia University Medical Center, New York, NY; 3Cardiology, Icahn School of Medicine at Mount Sinai, New York, NY; 4Cardiac Surgery, Columbia University Medical Center, New York, NY. Purpose: Combined organ transplants represented 4.2% of all heart transplants (HT) in 2014. Small single center studies have suggested a decreased risk of cardiac allograft vasculopathy (CAV) in dual organ transplantation compared with HT alone. This study sought to determine if combined solid organ transplantation is protective against CAV among patients propensity score matched for CAV risk factors. Methods: Patients who underwent HT, heart-kidney (HK), heart-lung (HLu), and heart-liver (HLi) transplant between Jan 1st, 1995 and Aug 31st, 2014 were identified in the UNOS registry. A propensity score was calculated using a non-parsimonious multivariable logistic regression model, including recipient CAV risk factors (age, sex, dyslipidemia, DM, HTN, BMI, ischemic etiology of heart failure, CMV status), donor CAV risk factors (# of HLA mismatches, age, sex, DM, HTN, tobacco use, BMI, CMV status, and intracerebral hemorrhage), and other clinical characteristics of interest (race, PRA> 10%, MCS use, former tobacco use). Kaplan-Meier survival analysis and adjusted Cox proportionalhazards regression adjusting for post-transplant MMF and PSI use were performed. Results: There were 38,862 HT patients and 1,524 dual organ transplant patients identified. Adjusted analysis of the cohort demonstrated a 38% decrease in the risk of developing CAV for those who underwent a dual organ transplant compared with those undergoing only HT (95% CI 0.63-0.82, p< 0 .0001). Propensity score matching produced 765 HK pairs, 117 HLi pairs, and 419 HLu pairs. There was a non-significant trend towards a decreased risk of CAV among HK (HR 0.84, 95% CI 0.63-1.11) and HLi (HR 0.71, 95% CI 0.32-1.58) recipients. HLu recipients had a 50% decreased risk of CAV (95% CI 0.31-0.79, p= 0 .003) on adjusted analysis. Conclusion: Dual organ recipients had a decreased risk of CAV, which was attributable to a 50% decreased risk with HLu transplant. The immunologic mechanism by which HLu transplant confers this benefit merits further investigation.
Impact of Cardiac Allograft Vasculopathy and Treated Rejection on Sudden Cardiac Death in Patients Receiving a Cardiac Transplant. An Analysis of the ISHLT Registry Data A.C. Alba ,1 C.S. Fan,2 C. Manlhiot,2 A.I. Dipchand,3 J. Stehlik,4 H.J. Ross.1 1Toronto General Hospital - University Health Network, Toronto, ON, Canada; 2The Hospital for Sick Children - University of Toronto, Toronto, ON, Canada; 3Heart Transplant Program, The Hospital for Sick Children - University of Toronto, Toronto, ON, Canada; 4University of Utah School of Medicine, Salt Lake City, UT. Purpose: Sudden cardiac death (SCD) is responsible for approximately 10% of post-heart transplant (HTx) deaths. Evidence from case series and cohort studies has shown controversial results about the effect of rejection and cardiac allograft vasculopathy (CAV) on the risk of SCD. We hypothesized that patients developing CAV and/or rejection will have different SCD risk. We tested this hypothesis in a retrospective cohort study. Methods: Adult HTx recipients from the ISHLT registry were included in this analysis. We excluded patients who died within 3 months of HTx. We used multivariable competing risk survival analysis to evaluate the association between any degree CAV or rejection and SCD risk accounting for other modes of death. CAV was entered as time-dependent covariate. Rejection was defined as any episode of treated rejection within the first 3 months after HTx. Other covariates in the model were recipient age and sex, type of cardiomyopathy, BMI at transplant, smoking history, pre-HTx diabetes, hypertension, renal function and pulmonary hypertension, prior use of mechanical circulatory support or intravenous inotropes and panel reactive antibodies. Results: In this cohort of 28,451 patients, the median (inter-quartile range) age was 54 (44-61) years, 24% patients were female. The incidence of CAV was 30% at 10 years and 7% had an episode of treated rejection in the first 3 months post-HTx. During a median follow up of 4 (2 - 6.8) years, 721 patients died suddenly. The incidence of SCD was 1.1%, 3% and 4.5% at 1, 6 and 10 years, respectively. Patients with CAV had a 22% increased risk of SCD (HR 1.22, 95%CI 1.11-1.35, p< 0.001). Treated rejection was not associated with a significantly higher SCD risk of SCD (HR 1.1, 95%CI 0.99-1.22, p= 0.089). However, patients with both CAV and history of treated rejection had a 66% significantly higher risk of SCD (HR 1.66, 95% CI 1.3-2.1, p< 0.001). Conclusion: The risk of SCD after HTx was significantly increased in patients with CAV. This risk was more pronounced if patients additionally had treated rejection early post-HTx. These results provide important information about the risk of SCD and the potential to identify patients who would benefit from implantable cardioverter defibrillator. 3( 94) Positron Emission Tomography Is Associated with the Presence of Cardiac Allograft Vasculopathy on Coronary Angiography M.C. Konerman ,1 J.J. Lazarus,1 R.L. Weinberg,1 M. Ghannam,1 A. Saleh,1 H. Yun,1 V.M. Moles,1 S.L. Hummel,1 R.V. Shah,2 J.R. Corbett,1 K.D. Aaronson,1 M.M. Colvin,1 T.M. Koelling,1 V.L. Murthy.1 1University of Michigan, Ann Arbor, MI; 2Beth Israel Deaconess Medical Center, Boston, MA.
The Journal of Heart and Lung Transplantation, Vol 36, No 4S, April 2017
Conclusion: Those with end-stage heart failure and renal failure represent a critically ill cohort of OHT candidates. In those requiring dialysis after listing for OHT, a SHK strategy confers superior survival compared to HTA or KAH. Future revisions to organ allocation should take into account both the appropriateness of SHK, as well as superiority of SHK over sequential transplant strategies.
3( 93)
3( 92) Attenuation of Cardiac Allograft Vasculopathy in Dual Organ Transplantation K.J. Clerkin ,1 S.W. Restaino,1 F. Latif,1 M.A. Farr,1 E. Zorn,2 D.M. Mancini,3 K. Takeda,4 H. Takayama,4 Y. Naka,4 P.C. Colombo,1 V.K. Topkara.1 1Cardiology, Columbia University Medical Center, New York, NY; 2Immunology, Columbia University Medical Center, New York, NY; 3Cardiology, Icahn School of Medicine at Mount Sinai, New York, NY; 4Cardiac Surgery, Columbia University Medical Center, New York, NY. Purpose: Combined organ transplants represented 4.2% of all heart transplants (HT) in 2014. Small single center studies have suggested a decreased risk of cardiac allograft vasculopathy (CAV) in dual organ transplantation compared with HT alone. This study sought to determine if combined solid organ transplantation is protective against CAV among patients propensity score matched for CAV risk factors. Methods: Patients who underwent HT, heart-kidney (HK), heart-lung (HLu), and heart-liver (HLi) transplant between Jan 1st, 1995 and Aug 31st, 2014 were identified in the UNOS registry. A propensity score was calculated using a non-parsimonious multivariable logistic regression model, including recipient CAV risk factors (age, sex, dyslipidemia, DM, HTN, BMI, ischemic etiology of heart failure, CMV status), donor CAV risk factors (# of HLA mismatches, age, sex, DM, HTN, tobacco use, BMI, CMV status, and intracerebral hemorrhage), and other clinical characteristics of interest (race, PRA> 10%, MCS use, former tobacco use). Kaplan-Meier survival analysis and adjusted Cox proportionalhazards regression adjusting for post-transplant MMF and PSI use were performed. Results: There were 38,862 HT patients and 1,524 dual organ transplant patients identified. Adjusted analysis of the cohort demonstrated a 38% decrease in the risk of developing CAV for those who underwent a dual organ transplant compared with those undergoing only HT (95% CI 0.63-0.82, p< 0 .0001). Propensity score matching produced 765 HK pairs, 117 HLi pairs, and 419 HLu pairs. There was a non-significant trend towards a decreased risk of CAV among HK (HR 0.84, 95% CI 0.63-1.11) and HLi (HR 0.71, 95% CI 0.32-1.58) recipients. HLu recipients had a 50% decreased risk of CAV (95% CI 0.31-0.79, p= 0 .003) on adjusted analysis. Conclusion: Dual organ recipients had a decreased risk of CAV, which was attributable to a 50% decreased risk with HLu transplant. The immunologic mechanism by which HLu transplant confers this benefit merits further investigation.
Impact of Cardiac Allograft Vasculopathy and Treated Rejection on Sudden Cardiac Death in Patients Receiving a Cardiac Transplant. An Analysis of the ISHLT Registry Data A.C. Alba ,1 C.S. Fan,2 C. Manlhiot,2 A.I. Dipchand,3 J. Stehlik,4 H.J. Ross.1 1Toronto General Hospital - University Health Network, Toronto, ON, Canada; 2The Hospital for Sick Children - University of Toronto, Toronto, ON, Canada; 3Heart Transplant Program, The Hospital for Sick Children - University of Toronto, Toronto, ON, Canada; 4University of Utah School of Medicine, Salt Lake City, UT. Purpose: Sudden cardiac death (SCD) is responsible for approximately 10% of post-heart transplant (HTx) deaths. Evidence from case series and cohort studies has shown controversial results about the effect of rejection and cardiac allograft vasculopathy (CAV) on the risk of SCD. We hypothesized that patients developing CAV and/or rejection will have different SCD risk. We tested this hypothesis in a retrospective cohort study. Methods: Adult HTx recipients from the ISHLT registry were included in this analysis. We excluded patients who died within 3 months of HTx. We used multivariable competing risk survival analysis to evaluate the association between any degree CAV or rejection and SCD risk accounting for other modes of death. CAV was entered as time-dependent covariate. Rejection was defined as any episode of treated rejection within the first 3 months after HTx. Other covariates in the model were recipient age and sex, type of cardiomyopathy, BMI at transplant, smoking history, pre-HTx diabetes, hypertension, renal function and pulmonary hypertension, prior use of mechanical circulatory support or intravenous inotropes and panel reactive antibodies. Results: In this cohort of 28,451 patients, the median (inter-quartile range) age was 54 (44-61) years, 24% patients were female. The incidence of CAV was 30% at 10 years and 7% had an episode of treated rejection in the first 3 months post-HTx. During a median follow up of 4 (2 - 6.8) years, 721 patients died suddenly. The incidence of SCD was 1.1%, 3% and 4.5% at 1, 6 and 10 years, respectively. Patients with CAV had a 22% increased risk of SCD (HR 1.22, 95%CI 1.11-1.35, p< 0.001). Treated rejection was not associated with a significantly higher SCD risk of SCD (HR 1.1, 95%CI 0.99-1.22, p= 0.089). However, patients with both CAV and history of treated rejection had a 66% significantly higher risk of SCD (HR 1.66, 95% CI 1.3-2.1, p< 0.001). Conclusion: The risk of SCD after HTx was significantly increased in patients with CAV. This risk was more pronounced if patients additionally had treated rejection early post-HTx. These results provide important information about the risk of SCD and the potential to identify patients who would benefit from implantable cardioverter defibrillator. 3( 94) Positron Emission Tomography Is Associated with the Presence of Cardiac Allograft Vasculopathy on Coronary Angiography M.C. Konerman ,1 J.J. Lazarus,1 R.L. Weinberg,1 M. Ghannam,1 A. Saleh,1 H. Yun,1 V.M. Moles,1 S.L. Hummel,1 R.V. Shah,2 J.R. Corbett,1 K.D. Aaronson,1 M.M. Colvin,1 T.M. Koelling,1 V.L. Murthy.1 1University of Michigan, Ann Arbor, MI; 2Beth Israel Deaconess Medical Center, Boston, MA.